News

John Barbieri, MD, MBA, discusses how deteriorating prior authorization processes are compromising access to essential dermatologic therapies.

An updated review offers effective alternatives to hydroquinone for melasma treatment, including thiamidol and natural agents, with improved safety profiles.

A meta-analysis of over 800,000 patients shows JAK inhibitors are generally as safe as TNF antagonists for various purposes.

Galderma initiates a pivotal study on nemolizumab, targeting Chronic Pruritus of Unknown Origin, aiming to provide relief for this challenging condition.

Explore the emerging concept of PDE4 inhibitor-responsive dermatoses, offering innovative nonsteroidal treatments for chronic inflammatory skin conditions.

President Biden's Mohs surgery highlights the need for equitable access to this effective skin cancer treatment, emphasizing its benefits and ongoing disparities.

Discover how the SkinCARE Questionnaire can measure the emotional impact of everyday skin health, enhancing understanding of skin-related wellbeing in healthy individuals.

Explore the long-term efficacy and safety of ligelizumab for CSU, highlighting self-administration success and significant symptom control.

FDA proposes adding bemotrizinol to sunscreen ingredients, enhancing UV regulations and protection options for consumers for the first time since 1999.

A new global study reveals hidradenitis suppurativa affects 1 in every 100 people, highlighting the need for increased awareness and improved health care strategies.

Discover how anatomical variations impact the minimal erythema dose in 308-nm excimer laser therapy for vitiligo in Asian patients.

Omar Noor, MD, discusses how pain and functional impairment define CHE and reviews why topical delgocitinib provides early symptomatic relief and improved adherence.

A nationwide survey in Japan reveals significant health-related quality of life and psychological challenges faced by patients with vitiligo, highlighting the need for better mental health support.

Comprehensive patch testing is vital for accurately diagnosing various forms of dermatitis, improving patient care, and addressing public health challenges.

MediWound reveals clinical data showing NexoBrid significantly reduces pigmentation in traumatic tattoos from abrasions and blast injuries.

Explore the latest advancements in chronic spontaneous urticaria (CSU) therapies, including innovative treatments and patient-centered management strategies.

This review of the latest dermatologic studies includes a review on JAK-induced acne, a case series of atypical pediatric-onset Behçet's Disease, research on drug survival in AD, and more.

Explore the emotional and physical challenges of chronic hand eczema through a patient's journey and expert insights on empathetic care and innovative treatments.

Lakshi Aldredge, MSN, ANP-BC, DCNP, discussed key symptoms of CHE, the function of the JAK-STAT pathway, and key data from the DELTA trials evaluating delgocitinib cream at the Horizons in Advanced Practice meeting.

Celldex is launching a phase 3 trial for barzolvolimab, targeting cold urticaria and symptomatic dermographism, offering hope for effective treatment options.

Discover the efficacy and safety of topical roflumilast 0.3% for psoriasis, highlighting its rapid results and potential for sensitive skin areas.

AI could revolutionize vitiligo management with enhanced diagnostics, automated tracking, and personalized treatment forecasting, improving patient care and outcomes.

Dermatology Times highlights 2025's innovations in dermatology, featuring new therapies, expert insights, and a look ahead to 2026 advancements.

John Barbieri, MD, MBA, outlines how missing reviewer identification, unclear step-therapy requirements, and limited engagement during appeals contribute to delays, inefficiencies, and potential clinical harm for patients.

PolarityBio advances SkinTE for diabetic foot ulcers, aiming for a breakthrough in chronic wound treatment with promising trial results announced soon.

Kymera Therapeutics reveals promising phase 1b results for KT-621, an oral STAT6 degrader, showing significant effects in moderate to severe atopic dermatitis.

Discover how hotel shampoos, conditioners, and body washes contribute to allergic contact dermatitis, revealing significant regional differences in allergen prevalence.

The first treatment follows Zevaskyn’s FDA approval as the first autologous, gene-modified cellular sheet designed to address RDEB wounds.